Brought to you by 
Resolvyx, NNRI in retinal disease collaboration
10 Dec 2008
Executive Summary
The National Neurovision Research Institute, the translational research arm of the Foundation Fighting Blindness, and Resolvyx Pharmaceuticals (produces oxidized omega-3 fatty acids that target inflammation) have agreed to develop the latter's resolvin drug candidates for retinal disorders, specifically inherited degenerative diseases such as dry AMD.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Resolvyx, NNRI in retinal disease collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice